The Cancer Registry of Norway has carried out research on human papillomavirus (HPV) and cancer, since the 1990s. Our research includes the incidence, prevention, natural course and development of cancer, as well as evaluation of the effect and safety of the HPV vaccine Gardasil in Norway and the Nordic countries. Projects that promote the idea of personalized mass screening have been initiated to optimize cancer screening.
Several HPV vaccines have been developed, including Cervarix for high-risk HPV16 and 18, and Gardasil 9 for high-risk HPV16, 18, 31, 33, 45, 52 and 58 as well as low-risk HPV6 and 11 that can cause genital warts. All HPV vaccines contain protection against HPV16 and 18, which are the most serious high-risk types. These two types of viruses cause around 70 percent of cervical cancer cases. All HPV vaccines are preventive and therefore most effective if given before exposure to HPV, i.e. before sexual debut.
Some of our ongoing research projects: